BACKGROUND:Granulocyte monocyte-colony stimulating factor (GM-CSF) supports the survival, expansion, and differentiation of lymphoid and myeloid derived dendritic cells (DCs). We hypothesized that systemic therapy with GM-CSF in prostate cancer patients could augment prostate cancer-related immunity and induce clinical response. METHODS:Eligible patients were randomly assigned to receive either 125 or 250 microg/m(2) GM-CSF subcutaneously three times a week until clinical progression. Prostate-specific antigen (PSA) T cell precursor frequencies were determined by a flow cytometric method. RESULTS: We were able to show, for the first time, a statistically significant correlation between pre-treatment PSA level and PSA-specific CD4(+) T cell precursors and a trend between pre-treatment PSA level and PSA-specific CD8(+) T cell precursors (P<0.0001 and P=0.059, respectively). CONCLUSIONS: These results suggest that existent immunity to PSA in prostate cancer patients may be a promising target for future immunotherapeutic approaches to prostate cancer. Prostate 66:667-674, 2006. (c) 2006 Wiley-Liss, Inc.
RCT Entities:
BACKGROUND:Granulocyte monocyte-colony stimulating factor (GM-CSF) supports the survival, expansion, and differentiation of lymphoid and myeloid derived dendritic cells (DCs). We hypothesized that systemic therapy with GM-CSF in prostate cancerpatients could augment prostate cancer-related immunity and induce clinical response. METHODS: Eligible patients were randomly assigned to receive either 125 or 250 microg/m(2) GM-CSF subcutaneously three times a week until clinical progression. Prostate-specific antigen (PSA) T cell precursor frequencies were determined by a flow cytometric method. RESULTS: We were able to show, for the first time, a statistically significant correlation between pre-treatment PSA level and PSA-specific CD4(+) T cell precursors and a trend between pre-treatment PSA level and PSA-specific CD8(+) T cell precursors (P<0.0001 and P=0.059, respectively). CONCLUSIONS: These results suggest that existent immunity to PSA in prostate cancerpatients may be a promising target for future immunotherapeutic approaches to prostate cancer. Prostate 66:667-674, 2006. (c) 2006 Wiley-Liss, Inc.
Authors: Joseph D Tario; Kristen Humphrey; Andrew D Bantly; Katharine A Muirhead; Jonni S Moore; Paul K Wallace Journal: J Vis Exp Date: 2012-12-13 Impact factor: 1.355
Authors: Anurag Mehta; Kreton Mavromatis; Yi-An Ko; Steven C Rogers; Devinder S Dhindsa; Cydney Goodwin; Risha Patel; Mohammad A Martini; Mahadev Prasad; Ali Mokhtari; Iraj G Hesaroieh; Stephen C Frohwein; Michael H Kutner; Arash Harzand; Bryan J Wells; Yazan Duwayri; Olamide Alabi; Ravi R Rajani; Luke P Brewster; Edmund K Waller; Arshed A Quyyumi Journal: Contemp Clin Trials Date: 2020-03-04 Impact factor: 2.226